# A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

> **NCT05621317** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Aravax Pty Ltd** · enrollment: 90 (estimated)

## Conditions studied

- Peanut Allergy
- Peanut Hypersensitivity
- Peanut-Induced Anaphylaxis
- Immune System Diseases

## Interventions

- **BIOLOGICAL:** PVX-108
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05621317
- **Lead sponsor:** Aravax Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-09
- **Primary completion:** 2025-11
- **Final completion:** 2027-06
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05621317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05621317, "A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05621317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*